Ricolinostat is at the most advanced stage of development and exemplifies the promising results of selective HDAC6 inhibition regarding the safety, tolerability, and efficacy in treating blood cancers such as leukaemia, multiple myeloma, and lymphoma [77,78,79,80,81]. Here, HDAC6 is linked to plasma cell myeloma.